EFPIA

While there is understandable concern in the medical profession that financial disclosure will fuel media sensation, the Dutch experience indicates that showing exactly how much was paid to who, for what, neutralises speculation, says Lode Wigersma, former director of the Royal Dutch Medical Association. To read the article by Lode Wigersma

The Dutch Pharmaceutical Advertising Code (Gedragscode Geneesmiddelenreclame, “CGR”) contains several new requirements concerning interactions between pharmaceutical companies and healthcare professionals (HCPs) which will apply as of 1 January 2015. To read this overview by Hogan Lovells may help to check whether your company is prepared, e.g. are internal procedures and templates up to date?

How does the pharmaceutical disclosure code affect health care providers? This event is part of EFPIA’s Responsible Transparency initiative, a public information campaign launched to boost pharmaceutical industry preparedness with complying to new disclosure rules for certain financial and other transfers of value with healthcare professionals and organisations. This event will inform the public on the progress of disclosure on a European and member state level. About the event

As Greece rebuilds after the financial crisis, adopting the EFPIA code on financial disclosure will be a source of greater confidence, improving the environment for investment and growth, says SFEE President Konstantinos Frouzis. The EFPIA code on transfers of value is “a very important development” that enables the national body in Greece, the Association of Pharmaceutical Companies (SFEE), to play its part in the nation’s recovery. To read the article by Konstantinos Frouzis

With only a few weeks to go, companies are ready to start collecting data and a wide-reaching communications campaign means physicians are now taking a pragmatic approach to disclosure of transfers of value, says Paweł Sztwiertnia, General Director of INFARMA, the Polish industry association. To read the article by Paweł Sztwiertnia

Member companies and organisations report good headway on the technical aspects of disclosure. Now it is critical to ensure that publishing transfers of value does not deter healthcare professionals from engaging with the industry, says Richard Bergström, Director General of EFPIA. To read the article by Richard Bergström